Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of IVA.PA is 9.0 and suggests 69% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell